Naltrexone for Alcohol Use Disorder: Effectiveness and Safety
Naltrexone is moderately effective for preventing alcohol relapse and reducing heavy drinking, with short-term treatment lowering the risk of relapse by approximately 17%, though it carries a risk of hepatocellular injury that requires careful monitoring, particularly at higher doses. 1
Effectiveness
Reduction in Heavy Drinking
Naltrexone demonstrates clear efficacy in reducing alcohol consumption among patients with alcohol use disorder:
- Reduces heavy drinking days by 25% compared to placebo when combined with psychosocial interventions 2
- Decreases overall drinking days by approximately 4% (MD -3.89 days) 2
- Lowers total alcohol consumption by roughly 11 units (MD -10.83) 2
- In controlled trials, abstinence rates reached 51% vs 23% with placebo, and relapse rates were 31% vs 60% 3
Clinical Context and Limitations
The evidence shows naltrexone works best when:
- Combined with counseling and psychosocial support - medication alone is insufficient 1
- Patients have already achieved initial abstinence - naltrexone maintains rather than induces abstinence 1
- External compliance support exists - the drug does not reinforce its own use like methadone 3
Critical caveat: Naltrexone is "not uniformly helpful to all patients" and produces only "a modest improvement in the outcome of conventional treatment" 3. The effect sizes, while statistically significant, are moderate in magnitude 2.
Safety Concerns
Hepatotoxicity - The Primary Risk
Naltrexone has been shown to cause hepatocellular injury, which is the most significant safety concern 1:
- Dose-dependent liver toxicity occurs at higher doses (up to 300 mg/day in studies) 3
- At therapeutic doses (50 mg/day), hepatotoxicity risk exists but is less pronounced
- Baseline liver function tests and monitoring every 3-6 months are mandatory 4
Contraindications in Liver Disease
Multiple guidelines explicitly state:
- Naltrexone is NOT recommended in patients with alcoholic liver disease (ALD) due to hepatotoxicity risk 5, 6
- Contraindicated in patients with acute hepatitis or liver failure 6
- For patients with cirrhosis or advanced liver disease, baclofen is the preferred alternative 1, 5
Common Adverse Effects
The most frequent side effects are generally mild 3:
- Gastrointestinal: Nausea (10% incidence, RD 0.10), vomiting (3%)
- Neurological: Headache (7%), dizziness (4%), sedation/daytime sleepiness (9%, RD 0.09)
- Psychiatric: Nervousness (4%), anxiety (2%), insomnia (3%)
- Discontinuation rate: Approximately 5% of patients stop due to nausea 3
Other Safety Considerations
- Cannot be used with concurrent opioid therapy - blocks pain relief from opioid medications 4
- Risk of precipitated withdrawal if patient is not completely opioid-free 3
- Depression and suicidal ideation rates (0-15%) are similar to placebo (0-17%), suggesting no causal relationship 3
Practical Prescribing Algorithm
Patient Selection
First-line candidates 1:
- Alcohol-dependent patients who have achieved initial detoxification/abstinence
- Normal liver function (no evidence of alcoholic liver disease)
- Motivated patients with psychosocial support structure
- Not requiring opioid pain medications
Avoid or use alternative 5, 6:
- Advanced alcoholic liver disease → use baclofen instead
- Liver function tests >3× normal or elevated bilirubin → use acamprosate instead
- Active opioid use or chronic pain requiring opioids → contraindicated
Dosing Regimen
Standard oral naltrexone 3:
- 50 mg once daily, or
- 100 mg on Monday/Wednesday, 150 mg on Friday (alternative schedule)
- Duration: 3-6 months minimum, up to 12 months
Long-acting injectable (Vivitrol) 7:
- 380 mg intramuscular monthly
- Shows 25% reduction in heavy drinking days (superior to 190 mg dose)
- Better treatment persistence than oral formulation 8
Monitoring Requirements
- Baseline liver function tests before initiation 4
- Repeat LFTs every 3-6 months during treatment 4
- Assess drinking patterns and psychosocial support adherence regularly
Comparative Effectiveness
Naltrexone vs. Acamprosate: Recent evidence suggests acamprosate may be superior for maintaining abstinence in primary care settings, with moderate-quality evidence supporting its use 9. Naltrexone and acamprosate showed no significant difference in a large RCT 1.
Naltrexone vs. Nalmefene: Both reduce heavy drinking days and total alcohol consumption, though nalmefene can be used "as needed" rather than daily 10, 11.
Injectable vs. Oral: Long-acting injectable naltrexone demonstrates 94% higher treatment persistence (OR 1.94) compared to oral formulation, particularly at 3 and 6 months 8, though healthcare utilization outcomes (ED visits, hospitalizations) show no difference.
Bottom Line for Clinical Practice
Use naltrexone as an adjunct to counseling in alcohol-dependent patients who have achieved initial abstinence and have normal liver function. The drug provides modest but meaningful reductions in heavy drinking and relapse risk. Absolutely avoid in patients with alcoholic liver disease - choose baclofen or acamprosate instead. Monitor liver function regularly, and recognize that the injectable formulation may improve adherence in appropriate candidates. The medication works best within a comprehensive treatment program, not as monotherapy.